Agile Therapeutics (AGRX) Has Upside Remaining - RBC Capital

RBC Capital maintains Outperform on Agile Therapeutics (NASDAQ: AGRX) price target of $8.00.

Analyst Randall Stanicky comments "We hosted meetings with AGRX with focus on approval path for lead contraceptive patch product Twirla. Risk appetite is needed given approval uncertainty but AGRX has solid case for approval given trial robustness. Based on materiality of upside potential, we do not think stock is appropriately pricing in risk-adjusted upside. AGRX targeting 4Q for approval and if so we still see take-out as realistic."

For an analyst ratings summary and ratings history on Agile Therapeutics click here. For more ratings news on Agile Therapeutics click here.

Shares of Agile Therapeutics closed at $2.24 yesterday.

You May Also Be Interested In

• Macquarie Double Upgrades Kinsus Interconnect Technology Corp (3189:TT) to Outperform
• Nurix (NRIX) PT Raised to $34 at Mizuho
• Western Midstream Partners (WES) PT Raised to $48 at UBS